U.S. Physical Therapy Posts Solid Growth Amidst Complex Earnings Picture
U.S. Physical Therapy Inc (NYSE:USPH), a national operator of outpatient physical therapy clinics, reported financial results for the fourth quarter and full year ended December 31, 2025. The company delivered robust top-line growth and improved profitability metrics, though its earnings per share presented a mixed picture when viewed through different accounting lenses, leading to a nuanced market reaction.
Earnings and Revenue Versus Estimates
For the fourth quarter of 2025, the company's performance relative to analyst expectations reveals a slight divergence between revenue and profit.
- Revenue: The company reported net revenue of $202.7 million for Q4 2025. This came in just below the analyst consensus estimate of approximately $204.4 million.
- Earnings Per Share (EPS): On a non-GAAP basis, which the company refers to as "Operating Results," U.S. Physical Therapy reported EPS of $0.67. This was a penny shy of the analyst estimate of $0.68.
However, the GAAP earnings picture was significantly impacted by non-cash accounting adjustments. Net income attributable to shareholders was $4.2 million, resulting in a GAAP loss per share of $0.44. This was primarily driven by an $18.0 million increase in the value of redeemable noncontrolling interests due to improved performance, a charge that flows through the per-share calculation under accounting rules but does not impact cash flow.
Market Reaction and Strategic Execution
The stock's performance following the report has been muted, with shares down approximately 5.5% over the past week. This reaction likely reflects the slight miss on consensus revenue and non-GAAP EPS estimates, combined with the headline GAAP loss. Investors may also be weighing the company's increased corporate costs related to system upgrades and acquisition integration against the strong operational growth.
Despite the market's near-term hesitation, the underlying operational results for the quarter were strong:
- Net revenue increased 13.0% year-over-year to $202.7 million.
- Physical therapy patient visits grew 11.2%, and the average net rate per visit improved to $106.49.
- Adjusted EBITDA, a key profitability metric, grew 13.5% to $24.8 million.
- Gross profit margin for physical therapy operations expanded to 20.2%, up from 18.3% in the prior-year quarter.
Full-Year Performance and Forward Guidance
For the full year 2025, the company demonstrated consistent growth, with revenue climbing 16.3% to $781.0 million. Adjusted EBITDA increased 16.2% to $95.0 million, and non-GAAP Operating Results per share rose to $2.63 from $2.45 in 2024.
Management provided guidance for 2026, expecting Adjusted EBITDA in the range of $102.0 million to $106.0 million. This outlook includes contributions from recent acquisitions and the initial phases of new strategic hospital alliances but assumes only a modest benefit from these partnerships as they ramp up through the year. The company's guidance range sets a baseline for growth, which analysts will compare to evolving consensus estimates for the coming year.
Key Highlights from the Report
Beyond the quarterly numbers, the press release outlined several significant strategic developments:
- Strategic Hospital Alliances: The company announced two major 10-year alliances, including one involving 60 clinics with a New York hospital system. These deals are expected to be accretive to revenue and EBITDA upon full integration.
- Recent Acquisitions: U.S. Physical Therapy completed two acquisitions in early 2026—an eight-clinic physical therapy practice and an industrial injury prevention business—continuing its growth-by-acquisition strategy.
- Capital Allocation: The Board of Directors approved a slight increase in the quarterly dividend to $0.46 per share and repurchased $5.6 million of stock in the fourth quarter.
- Leadership Transition: CFO Carey Hendrickson will resign in April 2026 to pursue another opportunity. Senior VP of Finance Jason Curtis will serve as interim CFO.
Conclusion
U.S. Physical Therapy's fourth quarter encapsulates a story of strong fundamental execution in clinic operations and strategic positioning, tempered by the mechanical complexities of its partnership structure and associated accounting. While the stock's recent weakness reflects a disappointment against specific consensus targets, the company's double-digit growth in visits, revenue, and core profitability, coupled with strategically valuable new hospital partnerships, suggests a foundation for continued expansion. The focus now shifts to the integration of recent acquisitions and the ramp-up of new alliances to meet the company's 2026 guidance.
For a detailed look at historical performance and future analyst estimates for U.S. Physical Therapy, you can review the earnings and estimates data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.